Vatinoxan hydrochloride is an antagonist of the peripheral α2 adrenergic receptors.

When given simultaneously i.v Vatinoxan alone increases cardiac index and tissue oxygen delivery and has no deleterious adverse effects.In a dose-dependent manner Vatinoxan attenuates or prevents dexmedetomidine's systemic hemodynamic effects. A 50:1 dose ratio (Vatinoxan:dexmedetomidine) induces the least alterations in cardiovascular function[1]. Vatinoxan dose-dependently reduces bradycardia associated with dexmedetomidine and shortens the sedative effect without changing its quality. Vatinoxan may help reduce heart rate reduction in cats consciously administering dexmedetomidine[2].

130466-38-5

C20H27ClN4O4S

454.97

MK-467 hydrochloride;L-659066 hydrochloride;Vatinoxan hydrochloride

H2O:133 mg/mL (292.33 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years